IMUNON, Inc. announced positive preliminary Phase 2 data for its DNA-mediated immunotherapy IMNN-001 in advanced ovarian cancer, showing lower minimal residual disease rates and higher circulating tumor DNA clearance compared to control. The therapy demonstrated a favorable safety profile, overcoming past IL-12 treatment barriers, and is now advancing in a Phase 3 trial. These results support IMNN-001's potential to improve frontline ovarian cancer treatment by remodeling the tumor immune environment and enhancing patient outcomes.
Over the past decade, an investment of $10,000 in AMD grew to more than $700,000, significantly outperforming the S&P 500, which turned the same amount into about $42,000. This highlights AMD's exceptional growth and strong market performance compare...
Gold prices surpassed $4,400 an ounce, pushing the VanEck Gold Miners ETF (GDX) to levels not seen in over ten years, rising nearly 18% in the past month. This surge is driven by strong free cash flows from major producers like Newmont and Agnico Eag...
Five popular income-focused ETFs—JEPI, JEPQ, QYLD, SPYI, and PFFA—offer different approaches to generating high yields. JEPI and JEPQ use covered-call strategies on large-cap and Nasdaq stocks, respectively, with JEPQ offering higher yields but more ...
Strategy Inc.'s STRC preferred stock rose 9% over the past year, outperforming Bitcoin which fell 47% during the same period. Other preferred securities from Strategy saw losses between 8% and 27%, while the company's common stock dropped about 76%. ...
SafePal, a crypto hardware wallet provider, revealed a data breach that exposed personal order details of 39,798 customers from March 2025 to April 2026. The breach exposed names, addresses, and contact info due to an authorization flaw in their orde...
